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Abstract 
Background: The metabolic syndrome (MetS) and its components are well-established risk factors for cardiovascular 
diseases (CVD). It is inconclusive whether MetS and MetS score are associated with electrocardiographic markers of 
subclinical CVD, therefore we investigated this in a population without pre-existing CVD.
Methods: We performed a cross-sectional analysis in the Netherlands Epidemiology of Obesity study, a population-
based cohort including 6671 participants aged 45–65. We excluded participants with pre-existing CVD (n = 499) or 
missing MetS components (n = 58). MetS was defined based on a modified definition of Adult Treatment Panel III. 
Subclinical CVD parameters were determined with 12-lead ECGs. MetS score was defined as number of abnormal 
MetS components and obesity as Body Mass Index (BMI) ≥30 kg/m2. We performed weighted adjusted linear regres-
sion analyses.
Results: Our study population (n = 6114) had a mean (SD) BMI of 26.3 (4.4) kg/m2 and MetS was present in 24% 
of participants. All ECG parameters differed between participants with and without MetS. Per additional MetS com-
ponent, heart rate was 0.17 SD (95% CI 0.15, 0.19) higher, P wave duration, QRS complex duration and corrected QT 
interval were longer [0.07 SD (0.05, 0.10), 0.04 SD (0.01, 0.06) and 0.05 SD (0.02, 0.08) respectively], P wave axis, T wave 
axis and QRS axis were lower [−0.10 SD (−0.12, −0.07), −0.07 SD (−0.10, −0.05) and −0.19 SD (−0.22, −0.16)] and 
percentage small Q-waves also increased per additional MetS component. Associations were stronger in non-obese 
than obese participants. In joint modelling of all MetS components, increased waist circumference showed strongest 
associations with ECG parameters.
Conclusions: Metabolic syndrome score and its individual components, in particular abdominal obesity, are associ-
ated with ECG markers of subclinical CVD, showing the importance of limiting the amount of MetS components in 
both obese and non-obese persons.
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Background
Cardiovascular disease (CVD) is the number one cause 
of death worldwide [1]. Metabolic syndrome (MetS) is a 
combination of cardiovascular risk factors such as obe-
sity, hyperglycemia, dyslipidemia and hypertension, and 
has been associated with increased risk of CVD. A recent 
meta-analysis showed that individuals with MetS had a 
twofold increased risk of CVD and a 1.5-fold increased 
risk of all-cause mortality [2]. In a study including 4122 
participants with a mean follow-up of 8.5  years, the 
risk of coronary heart disease increased with increas-
ing number of MetS components [3]. In addition, there 
are also studies showing that separate components are 
more important for the risk of different outcomes than 
the combination of components in MetS [4, 5]. Obesity 
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is a key component in MetS, becoming more relevant 
because of its increasing prevalence. However, there are 
also people who are metabolically unhealthy, but non-
obese. Also, in these individuals there is a higher preva-
lence of diabetes and CVD [6]. Therefore it is important 
to understand the relation between MetS and its compo-
nents and subclinical CVD in both non-obese and obese 
subpopulations.
Some previous studies investigated the association 
between MetS and subclinical CVD. Presence of MetS 
was associated with increased arterial stiffness, higher 
resting heart rate, prolonged QRS and prolonged QT 
interval and an abnormal T-wave axis [7, 8]. However, 
associations of MetS with subtle changes in electrocar-
diographic markers, indicative of subclinical CVD, are 
not fully elucidated. Few studies investigated these asso-
ciations in both non-obese and obese subpopulations. 
Knowledge on these associations may give more insight 
in possible population consequences of subtle ECG 
changes. Therefore, our objectives were to investigate 
the associations of MetS with subclinical CVD, of the 
number of abnormal MetS components with subclini-
cal CVD and to investigate whether these associations 
differ between obese and non-obese individuals without 
pre-existing CVD within the Netherlands Epidemiology 
of Obesity (NEO) study. Furthermore, we investigated 
contributions of separate MetS components to subclini-
cal CVD.
Methods
Study design and population
The NEO study is a population-based, prospective cohort 
study comprising 6671 individuals, included between 
2008 and 2012 and aged between 45 and 65  years [9]. 
Participants with BMI of 27  kg/m2 or higher were over-
sampled and also all inhabitants aged between 45 and 
65 years from one municipality (Leiderdorp) were invited 
irrespective of their BMI, allowing for a reference distri-
bution of BMI. Participants were invited to a baseline visit 
at the NEO study centre of the Leiden University Medical 
Center (LUMC) after an overnight fast. During this visit 
all participants underwent an extensive physical exami-
nation, including blood sampling and ECG. Participants 
completed a questionnaire with demographic, lifestyle, 
and clinical information. We excluded participants with 
missing values of waist circumference, glucose, triglyc-
erides, HDL-cholesterol or blood pressure. Furthermore, 
participants with pre-existing CVD, defined as myocar-
dial infarction, angina, congestive heart failure, stroke, or 
peripheral vascular disease, were excluded. The Medical 
Ethical Committee of the LUMC approved the design of 
the study. All participants gave informed consent.
Data collection
Ethnicity was reported by the participants in eight cat-
egories and grouped into white and other. Level of edu-
cation was reported in 10 categories according to the 
Dutch education system and grouped as low (none, pri-
mary school of lower vocational education) versus high. 
Tobacco smoking was categorized into current, former, 
or never smoker. Alcohol consumption was reported 
using a food frequency questionnaire and calculated into 
grams/day. Physical activity was reported using the Short 
Questionnaire to Assess Health-enhancing physical 
activity (SQUASH) questionnaire [10]. Energy expended 
during physical activity was calculated in leisure time in 
hours per week of metabolic equivalents (MET-h/week). 
Participants were asked to bring the medication they 
were currently using to the study visit and to report their 
medical history of diabetes or CVD. Height and weight 
were measured without shoes and 1  kg was subtracted 
from the weight to correct for clothing. BMI was calcu-
lated by dividing weight in kilograms by height in meters 
squared. Waist circumference was measured with a hori-
zontally placed flexible tape in the middle of the distance 
between the lowest rib and the iliac crest. Brachial blood 
pressure was measured in seated position on the right 
arm using a validated automatic oscillometric device 
(OMRON, Model M10-IT, Omron Health Care Inc, IL, 
USA). Blood pressure was measured three times with 
5  min rest between consecutive measurements. Mean 
systolic and diastolic blood pressure were calculated. 
Blood plasma was sampled after an overnight fast of 10 h. 
Fasting glucose, triglyceride and high-density lipoprotein 
concentrations were measured with the enzymatic color-
imetric method (Roche Modular Analytics P800, Roche 
Diagnostics Mannheim, Germany).
A 12-lead ECG was obtained using a Mortara Eli-350 
electrocardiograph (Mortara Instrument Inc., Best, the 
Netherlands) after a resting period of at least 10  min. 
ECGs were analysed using the automatic MATLAB-
based (The MathWorks, Natick, MA) program BEATS 
and the semiautomatic program LEADS [11, 12]. ECGs 
were also provided to the University of Glascow ECG 
core lab where Minnesota Codes were determined [13–
15]. In order to assess subtle changes in ECG parameters, 
that could indicate subclinical CVD in a population with-
out known overt cardiovascular diseases, heart rate, P 
wave duration, QRS complex duration, PR interval, cor-
rected QT interval (corrected according to the Bazett 
formula), P-, T- and QRS axis were determined. Further-
more, small Q-waves were assessed using the Minnesota 
Coding System, which is a system to objectively describe 
electrocardiographic findings. We defined small Q-waves 
as Minnesota Codes 1.2.x or 1.3.x.
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These ECG parameters are known to be of prognostic 
importance for CVD development [16–19].
Metabolic syndrome definition
The definition of MetS as proposed by the National 
Cholesterol Education Program Adult Treatment Panel 
III was used, with minor modifications as stated in the 
American Heart Association and the National Heart, 
Lung, and Blood Institute statement [20]. MetS is defined 
as the presence in an individual of at least three out of 
the five following criteria: (1) increased waist circumfer-
ence (>102  cm for men,  >88  cm for women); (2) raised 
serum triglyceride levels (1.7 mmol/L) or on drug treat-
ment to reduce triglyceride concentrations; (3) reduced 
serum HDL-cholesterol levels (1.03  mmol/L for men, 
1.3 mmol/L for women) or on drug treatment to elevate 
HDL-cholesterol; (4) raised blood pressure (≥130 mmHg 
systolic/≥85  mmHg diastolic) or on antihyperten-
sive drug treatment; (5) raised fasting plasma glucose 
(5.56  mmol/L) or on drug treatment to lower glucose 
concentrations. Obesity is defined as BMI ≥30 kg/m2 and 
MetS score as total number of MetS components present 
in an individual.
Statistical analysis
To correctly represent associations in the general popu-
lation, adjustments for the oversampling of participants 
with BMI of 27 kg/m2 or higher were made by weighting 
individuals towards the BMI distribution of participants 
from the Leiderdorp municipality whose BMI distribu-
tion was similar to that of the general Dutch population 
[21, 22].
Baseline characteristics were summarized as mean (SD) 
or percentage and stratified by the presence of MetS. We 
examined the associations between MetS and the ECG 
parameters heart rate (bpm), P wave duration (ms), QRS 
complex duration (ms), PR interval (ms), corrected QT 
interval (ms), P- (°), T- (°), QRS axis (°) and percentage of 
small Q-waves using linear regression analysis.
We calculated Z-scores and standardized the ECG 
parameters to a mean of zero with a standard deviation 
of one, in order to express the associations in SDs and 
compare them with each other. Next, we performed 
linear regression analyses with MetS score (0–5) as the 
independent and standardized ECG parameters as the 
outcome variables. To investigate differences in asso-
ciations between obese and non-obese persons, we 
tested for interaction with obesity by including prod-
uct terms of obesity and MetS in all models. Finally, 
to investigate the separate contributions of the MetS 
components in relation to the ECG parameters, we 
included all MetS components (dichotomous) in one 
joint model.
Crude associations were adjusted for age, sex, ethnicity, 
smoking, alcohol intake, education level, physical activity, 
and statin use. Data were analysed using STATA version 
14.
Results
Of the 6671 participants included in the NEO study, we 
consecutively excluded participants with a history of 
CVD (n = 499), missing data on fasting plasma glucose 
or glucose lowering therapy (n = 45), blood pressure or 
use of antihypertensive therapy (n = 7), waist circumfer-
ence (n = 4) and serum triglycerides or use of medication 
to reduce triglyceride concentrations (n  =  2). We ulti-
mately included 6114 participants. Baseline characteris-
tics are shown in Table  1. Of the participants, 24% met 
MetS criteria. Participants with MetS were more often 
Table 1 Baseline characteristics of  NEO study population 
without pre-existing CVD
Data are presented as mean (SD), median (IQR) or percentage. Results were 
based on analyses weighted towards the BMI distribution of the general 
population
BMI Body Mass Index, MET metabolic equivalent of task
a Lower education: none, primary school, lower vocational education
Metabolic syndrome
No (76%) Yes (24%)
Age, years 55.3 (5.2) 56.5 (7.9)
Sex, men, % 39.9 52.6
Ethnicity, white, % 95 96
BMI, kg/m2 25.0 (3.0) 30.1 (6.4)
Smoking, %
 Never 40.8 33.5
 Former 44.3 48.0
 Current 14.9 18.5
Alcohol intake, g/dag 9.7 (3.2–20.9) 10.4 (2.0–24.6)
Physical activity, MET-hour/week 30.9 (16.9–51.0) 25.8 (11.8–45.2)
Education level, low, (%)a 16.0 28.0
Fasting plasma glucose, mg/dL 93.7 (88.3–98.9) 105.7 (98.9–114.2)
Use of glucose lowering therapy, 
%
0.6 7.6
Systolic blood pressure (mmHg) 127.6 (14.1) 137.6 (22.6)
Diastolic blood pressure (mmHg) 81.7 (8.5) 87.9 (13.4)
Use of antihypertensive therapy, 
%
14.5 40.3
Waist circumference (cm)
 Men 94.4 (7.7) 106.9 (13.9)
 Women 83.6 (9.0) 101.1 (15.4)
Triglycerides, mg/dL 78.8 (59.3–106.3) 160.3 (111.6–208.1)
HDL, mg/dL
 Men 55.8 (11.0) 43.3 (15.4)
 Women 71.5 (13.9) 53.4 (18.8)
Use of lipid lowering therapy,  % 4.8 18.8
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men, current or former smoker and had a lower educa-
tional level. By definition, all other cardiovascular risk 
factors were more often present in the participants with 
MetS.
Crude and adjusted weighted linear regression analyses 
were performed to compare ECG parameters between 
participants with and without MetS. Participants with 
MetS had higher values of heart rate, P wave duration, 
QRS complex duration, PR interval and corrected QT 
interval, and lower values of P, T and QRS axis, i.e. more 
superiorly oriented axes. Furthermore, small Q-waves 
were more often present in participants with MetS (Addi-
tional file 1: Table S1). Table 2 shows this analysis for the 
non-obese and obese participants separately. In the non-
obese population, heart rate (difference: 5.0 bpm; 95% CI 
3.9, 6.2), P wave duration (2.3 ms; 0.9, 3.6), P axis (−4.3°; 
−6.8, −1.9), T axis (−2.8°; −5.5, −0.1), QRS axis (−13.3°; 
−16.6, −10.1) and small Q-waves (2.8%; 0.2, 5.4) differed 
between participants with and without MetS and in the 
obese population, there were differences in heart rate 
(3.1  bpm; 2.2, 4.0), corrected QT interval (2.2  ms; 0.2, 
4.2) and QRS axis (−2.9°; −5.3, −0.5).
Figure  1 displays regression lines per SD of the ECG 
parameters used in a linear regression analysis per MetS 
component, with panel A showing all ECG parameters 
that increased and panel B showing all ECG parameters 
that decreased with increasing number of components. 
Per additional MetS component, heart rate, P wave dura-
tion, QRS complex duration and QTc interval increased 
and P-, T- and QRS axis decreased. In Table 3, the asso-
ciation of MetS score, ranging from zero to five, with 
Z-scores of ECG parameters is shown for obese and 
non-obese participants separately. For P wave duration 
(p  =  0.027), P axis (p  =  0.001), T axis (p  <  0.001) and 
QRS axis (p  <  0.001) the interaction terms between 
MetS score and obesity were statistically significant. In 
the non-obese participants, with each additional MetS 
component, P wave duration was 0.05 SD (95% CI 0.02, 
0.09) longer, P axis was 0.08 SD (0.05, 0.12) lower, T axis 
was 0.07 SD (0.04, 0.11) lower and QRS axis was 0.17 SD 
(0.13, 0.21) lower. In the obese participants, P wave dura-
tion, P axis and T axis were not associated with increas-
ing amount of MetS components, whereas QRS axis 
was 0.05 SD (0.02, 0.08) SD lower with each additional 
component, but this was less than in the non-obese par-
ticipants. Furthermore, in non-obese participants per-
centage small Q-waves increased with each additional 
MetS component (4.5; 4.7; 6.8; 7.5; 11.6; 12.3%), while 
this was less clear in obese participants (0; 6.1; 8.8; 9.6; 
9.2; 8.3%).
In a joint model including all separate MetS components 
together with potential confounding factors (Table  4), 
high waist circumference was associated with all ECG 
parameters. High waist circumference was associated with 
2.4 bpm (95% CI 1.6, 3.2) higher heart rate, 3.4 ms (2.2, 4.4) 
longer P wave duration, 1.0 ms (0.1, 1.9) longer QRS com-
plex duration, 2.4 ms (0.6, 4.3) longer PR interval, 2.7 ms 
(1.0, 4.3) longer corrected QT interval, 7.4° (5.3, 9.4) lower 
P axis, 5.2° (3.3, 7.1) lower T axis, 12.9° (10.5, 15.2) lower 
QRS axis and 1.9% (0.2, 3.6) more small Q-waves. In this 
joint model, hypertriglyceridemia was only associated 
with heart rate, reduced serum HDL-cholesterol with P 
wave duration, PR interval and QRS axis, increased blood 
pressure with heart rate, P wave duration, QRS complex 
duration, corrected QT interval, T axis and QRS axis and 
hyperglycemia with heart rate and PR interval.
Table 2 Differences in baseline ECG parameters between non-obese and obese participants with and without metabolic 
syndrome
Data are presented as mean (se) or percentage
Results were based on weighted linear regression analysis adjusted for age, sex, ethnicity, smoking, alcohol intake, education level, physical activity and statin use
MetS metabolic syndrome
Non-obese (84%) Obese (16%)
ECG parameter No MetS (83%) MetS (17%) Diff (95% CI) No MetS (n = 36%) MetS (64%) Diff (95% CI) p value int
Heart rate (bpm) 62.4 (0.2) 67.7 (0.5) 5.0 (3.9, 6.2) 65.8 (0.3) 68.8 (0.3) 3.1 (2.2, 4.0) 0.006
P duration (ms) 110.9 (0.4) 114.3 (0.6) 2.3 (0.9, 3.6) 115.2 (0.5) 115.8 (0.4) −0.6 (−1.8, 0.6) 0.002
QRS duration (ms) 92.3 (0.3) 94.5 (0.5) 0.8 (−0.4, 2.0) 92.9 (0.4) 95.0 (0.3) 0.7 (−0.3, 1.7) 0.985
PR interval (ms) 162.1 (0.6) 166.3 (1.0) 2.4 (−0.1, 4.8) 163.9 (0.8) 164.8 (0.6) −1.1 (−3.0, 0.9) 0.029
QTc interval (ms) 413.7 (0.6) 414.7 (1.0) 1.2 (−1.0, 3.4) 416.1 (0.9) 418.2 (0.6) 2.2 (0.2, 4.2) 0.373
P axis (°) 49.0 (0.7) 44.2 (1.0) −4.3 (−6.8, −1.9) 40.4 (0.8) 40.6 (0.6) −0.2 (−2.3, 1.9) 0.001
T axis (°) 39.4 (0.6) 36.2 (1.1) −2.8 (−5.5, −0.1) 32.3 (0.8) 34.4 (0.7) 2.0 (−0.2, 4.2) 0.001
QRS axis (°) 39.8 (0.8) 23.0 (1.4) −13.3 (−16.6, −10.1) 23.2 (1.0) 18.4 (0.8) −2.9 (−5.3, −0.5) <0.001
Small Q-wave (%) 5.2 9.1 2.8 (0.2, 5.4) 8.1 9.3 0.7 (−1.7, 3.0) 0.121
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Fig. 1 ECG parameters in relation to metabolic syndrome score. Regression lines are shown for the different ECG parameters. ECG parameters 
are expressed in Z-scores. a ECG parameters that increased with increasing number of metabolic syndrome components; b ECG parameters that 
decreased with increasing number of metabolic syndrome components. Results were based on weighted analysis adjusted for age, sex, ethnicity, 
smoking, alcohol intake, education level, physical activity and statin use
Table 3 Relation of standardized ECG parameters to metabolic syndrome scores (range 0–5)
Data are presented as β (95% CI); change in Z-score of ECG parameter per metabolic syndrome component. Results were based on weighted analysis. Multivariate 
model adjusted for age, sex, ethnicity, smoking, alcohol intake, education level, physical activity and statin use
ECG parameter All Non-obese (84%) Obese (16%) p value int
Heart rate 0.17 (0.15, 0.19) 0.16 (0.13, 0.19) 0.12 (0.09, 0.16) 0.137
P duration 0.07 (0.05, 0.10) 0.05 (0.02, 0.09) 0.00 (−0.04, 0.03) 0.027
QRS duration 0.04 (0.01, 0.06) 0.02 (−0.01, 0.06) 0.04 (0.00, 0.07) 0.466
PR interval 0.01 (−0.02, 0.04) 0.00 (−0.04, 0.04) 0.01 (−0.03, 0.04) 0.866
QTc interval 0.05 (0.02, 0.08) 0.04 (0.00, 0.07) 0.05 (0.01, 0.09) 0.335
P axis −0.10 (−0.12, −0.07) −0.08 (−0.12, −0.05) −0.01 (−0.05, 0.02) 0.001
T axis −0.07 (−0.10, −0.05) −0.07 (−0.11, −0.04) 0.04 (0.00, 0.08) <0.001
QRS axis −0.19 (−0.22, −0.16) −0.17 (−0.21, −0.13) −0.05 (−0.08, −0.02) <0.001
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Discussion
We observed that electrocardiographic markers of sub-
clinical CVD differed between participants with and 
without MetS, indicating more subclinical CVD in par-
ticipants with than without MetS. ECG parameters 
associated with subclinical CVD increased with every 
additional MetS component present in an individual and 
for P wave duration, P axis, T axis and QRS axis, these 
associations were stronger in the non-obese than the 
obese population. Furthermore, in joint models includ-
ing all MetS components high waist circumference was 
associated with all ECG parameters whereas results for 
the other components were less strong.
In this study, subclinical CVD was investigated by look-
ing at subtle changes in ECG parameters. Although the 
observed changes are small and not per se of direct prog-
nostic significance on the individual level, they give more 
insight on a population level. All ECG parameters inves-
tigated, have previously been associated with a broad 
range of future cardiovascular abnormalities, events or 
mortality [16–18, 23–27].
Differences between participants with and without 
MetS have also been demonstrated in other studies. In 
a study with 6765 participants aged 45–84  years, MetS 
was associated with ECG abnormalities [28]. The associa-
tion of MetS with higher heart rate and also lower heart 
rate variability, indicative of an adverse effect of MetS 
on the cardiac autonomic modulation has previously 
been reported in literature [29, 30]. Furthermore MetS 
has been associated with borderline or abnormal T axis 
[31]. Furthermore, in a study that included both individu-
als with MetS as well as their offspring, evidence of early 
subclinical cardiovascular damage was found in individu-
als with MetS as well as their offspring [32]. In our study 
associations between MetS and ECG parameters are con-
firmed in a large group of extensively phenotyped indi-
viduals and on top of that we showed that it is important 
to pay attention to asymptomatic patients, with just zero 
or one component present, to prevent the increase of 
MetS components in these individuals and thereby also 
the development of CVD. We showed that this is already 
important in the non-obese population, since the asso-
ciations of MetS with subclinical CVD are also present in 
this population.
We observed associations between the presence of 
MetS and also MetS score and ECG parameters. Thus 
far, literature is inconclusive about the risk associated 
with MetS components and increasing MetS score. In a 
study with 9406 participants, it was concluded that MetS 
was not associated with 1-year mortality, while reduced 
HDL-cholesterol was associated with higher risk and 
raised triglycerides were associated with lower 1-year 
mortality risk [5]. In a case–control study, MetS was 
associated with higher risk of venous thromboembolism. 
However, after multivariate analysis, only abdominal 
obesity was associated with higher risk [4]. There are also 
studies stating that increasing MetS score can be used as 
a risk factor for CVD [33, 34]. Moreover, it was shown 
that MetS is associated with increased heart failure risk 
in individuals without diabetes or baseline macrovascular 
complications [35].
Associations between ECG parameters and MetS score 
seemed stronger in the non-obese population. A possi-
ble explanation is that obese participants are more likely 
to have a high waist circumference and also worse ECG 
parameters, so they have less variation in their MetS score 
which varies from zero to five. Nevertheless, our study 
shows that in non-obese participants every additional 
component contributes to the association with subclinical 
CVD. However, pathophysiological mechanisms underly-
ing this difference between non-obese and obese partici-
pants remain unclear from existing literature.
Furthermore, in the analysis of MetS components sepa-
rately (Table  4), we are aware that when adjusting the 
Table 4 Influence of metabolic syndrome components on ECG parameters
Data are presented as β (95% CI). Results were based on weighted analysis
Multivariate model adjusted for age, sex, ethnicity, smoking, alcohol intake, education level, physical activity, statin use and the other MetS components
ECG parameter Waist circumference Triglycerides HDL-cholesterol Blood pressure Fasting glucose
Heart rate (bpm) 2.4 (1.6, 3.2) 3.2 (2.2, 4.1) −0.3 (−1.2, 0.7) 1.8 (1.1, 2.5) 2.2 (1.4, 3.1)
P duration (ms) 3.4 (2.3, 4.4) −0.6 (−1.9, 0.7) 1.7 (0.3, 3.0) 1.1 (0.0, 2.2) −0.8 (−2.0, 0.4)
QRS duration (ms) 1.0 (0.1, 1.9) −0.5 (−1.5, 0.6) 0.2 (−0.8, 1.2) 1.4 (0.4, 2.4) −0.1 (−1.1, 1.0)
PR interval (ms) 2.4 (0.6, 4.3) −1.5 (−3.9, 0.8) 3.6 (1.2, 6.1) 0.4 (−1.6, 2.5) −3.5 (−5.4, −1.6)
QTc interval (ms) 2.7 (1.0, 4.3) 0.1 (−2.0, 2.1) 1.8 (−0.1, 3.8) 1.9 (0.2, 3.7) −0.9 (−2.7, 1.0)
P axis (°) −7.4 (−9.4, −5.3) −0.6 (−2.9, 1.6) −2.0 (−4.6, 0.6) −1.9 (−4.1, 0.2) 1.0 (−1.3, 3.2)
T axis (°) −5.2 (−7.1, −3.3) −0.2 (−2.5, 2.2) −2.0 (−4.4, 0.4) −2.7 (−4.7, −0.8) 1.2 (−0.8, 3.2)
QRS axis (°) −12.9 (−15.2, −10.5) −2.5 (−5.5, 0.5) −4.5 (−7.7, −1.4) −5.6 (−8.2, −3.0) −2.7 (−5.4, 0.0)
Small Q-wave (%) 1.9 (0.2, 3.6) 1.6 (−0.7, 3.9) 0.7 (−1.7, 3.2) 1.0 (−0.8, 2.8) 0.4 (−1.6, 2.3)
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associations of increased waist circumference and sub-
clinical CVD, it is possible that adjustments are made 
for factors that might partially be in the causal pathway. 
However, this would dilute the associations, so the true 
association between increased waist circumference and 
subclinical CVD might even be stronger than the associa-
tion that we find.
It is inconclusive through which mechanisms obesity 
or increased waist circumference lead to ECG abnor-
malities. Possibilities are increased sympathetic system 
activity, elevation of the diaphragm and increased cardiac 
output leading to left ventricular hypertrophy [36, 37]. 
Body fat was associated with measures of sympathetic 
activation in subjects with structurally normal hearts in 
the NEO study [38]. The leftward (superior) shifts of the 
T-, P- and QRS axis were associated with obesity in other 
studies [39–41]. Obesity can lead to an increase in car-
diac loading and remodelling of the heart muscle leading 
to PR interval lengthening [42]. Also hormones produced 
by the adipose tissue influence the myocardial matrix, 
resulting in electrophysiological remodelling [42]. Also 
endovascular effects of obesity are present, induced by 
paracrine hormone expression of the adipose tissue that 
could alter the atrial function [43].
A strength of this study is the large study population 
(n = 6114) and the extensive measurements of potential 
confounding factors that were performed in the NEO 
study. A weakness is its observational cross-sectional 
design, precluding any conclusions about causality of the 
observed relationships.
On the basis of its observed relation with ECG param-
eters, we conclude that MetS is associated with subtle 
changes in ECG parameters, indicative of more subclini-
cal CVD. As these ECG parameters are predictive of 
CVD and MetS score was associated with higher val-
ues of these parameters, MetS could be used as an early 
marker for subclinical CVD risk stratification, and to 
manage risks already in an early disease state. Further-
more, prevention of the development of MetS compo-
nents is important in obese, but also very relevant in 
non-obese individuals.
Conclusions
Metabolic syndrome score and its individual compo-
nents, in particular abdominal obesity, are associated 
with ECG markers of subclinical CVD in both obese and 
non-obese persons.
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